Klinische Studie
NAD+ supplement shows early promise for long COVID fatigue and brain fog
Von KI berichtet Bild generiert von KI Fakten geprüft
A randomized controlled trial at Massachusetts General Hospital tested high-dose nicotinamide riboside, a vitamin B3 derivative, to boost NAD+ levels in people with long COVID. Although between-group differences were limited, participants who took the supplement for at least 10 weeks reported improvements in fatigue, sleep, mood, and some executive function measures compared with their own baseline, suggesting potential benefits for some individuals despite mixed overall results.
Scientists at the University of Southern California are starting a phase 2b clinical trial to test a microscopic stem cell implant aimed at restoring vision in patients with advanced dry age-related macular degeneration. The hair-thin patch seeks to replace damaged retinal cells, building on earlier research that showed safety and vision gains in some participants. Researchers hope it could offer a way to reverse vision loss where current treatments fall short.
Von KI berichtet
Das Comandante Faustino Pérez Provinzialklinische Chirurgische Krankenhaus hat eine klinische Studie mit dem kubanischen Medikament Jusvinza zur Behandlung der residualen Polyarthritis bei Chikungunya-Überlebenden gestartet. Die Studie bewertet die Fähigkeit des Medikaments, anhaltende Schmerzen und Gelenkentzündungen zu reduzieren. Sie umfasst 120 Patienten und zielt auf eine erschwingliche Behandlungsoption ab.